Trousseau's Syndrome in Association with Cholangiocarcinoma: Positive Tests for Coagulation Factors and Anticardiolipin Antibody.
10.3346/jkms.2006.21.1.155
- Author:
Jeong Won JANG
1
;
Chang Dong YEO
;
Jin Dong KIM
;
Si Hyun BAE
;
Jong Young CHOI
;
Eun Sun JUNG
;
Sung Eun RHA
;
Jae Young BYUN
;
Seung Kew YOON
Author Information
1. Department of Internal Medicine, College of Medicine, WHO Collaborating Center on Viral Hepatitis, The Catholic University of Korea, Seoul, Korea. yoonsk@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Cholangiocarcinoma;
Pulmonary Embolism;
Heparin;
Heparin, Low-Molecular-Weight
- MeSH:
Antibodies, Anticardiolipin/blood;
Anticoagulants/therapeutic use;
Bile Duct Neoplasms/*complications;
*Bile Ducts, Intrahepatic;
Blood Coagulation Factors/analysis;
Cholangiocarcinoma/*complications;
Fibrin Fibrinogen Degradation Products/analysis;
Fibrinogen/analysis;
Heparin, Low-Molecular-Weight/therapeutic use;
Humans;
Male;
Middle Aged;
Pulmonary Embolism/*blood/drug therapy/etiology;
Syndrome;
Treatment Outcome
- From:Journal of Korean Medical Science
2006;21(1):155-159
- CountryRepublic of Korea
- Language:English
-
Abstract:
Thromboembolic events are reported to occur with a high frequency in the setting of malignancy. However, reports on an association between cholangiocarcinoma and pulmonary thromboembolism, thus far, are almost lacking. We present here an unusual case of a 56-yr-old patient presenting cholangiocarcinoma and unexplained pulmonary thromboembolism. The patient had been quite healthy before the diagnosis. Coagulation tests showed elevated levels of fibrinogen, fibrinogen degradation product (FDP), D-dimer, and IgM anticardiolipin antibody (aCL Ab). The thromboemboli were resolved 3 weeks after anticoagulant therapy using lowmolecular-weight-heparin. Then, follow-up coagulation tests showed a marked decrease to normal in aCL Ab titer as well as the normalization of FDP and D-dimer levels. In this case, we describe pulmonary thromboembolism caused by hypercoagulable state associated with cholangiocarcinoma and speculate that such a thrombotic phenomenon could be regressed by anticoagulant therapy.
